2.Effect of intermittent versus daily inhalation of budesonide on pulmonary function and fractional exhaled nitric oxide in children with mild persistent asthma.
Zhen-Hua ZHANG ; Wen-Xuan LI ; Xiao-Ming WANG
Chinese Journal of Contemporary Pediatrics 2020;22(8):834-838
OBJECTIVE:
To study the effect of intermittent versus daily inhalation of budesonide on pulmonary function and fractional exhaled nitric oxide (FeNO) in children with mild persistent asthma.
METHODS:
A total of 120 children, aged 6-14 years, with mild persistent asthma who attended the hospital from January 2016 to January 2018 were enrolled. The children were divided into an intermittent inhalation group with 60 children (inhalation of budesonide 200 μg/day for 6 weeks when symptoms of asthma appeared) and a daily inhalation group with 60 children (continuous inhalation of budesonide 200 μg/day) by stratified randomization. The children were followed up at months 3, 6, 9, and 12 of treatment. The two groups were compared in terms of baseline data, changes in FeNO and pulmonary function parameters, amount of glucocorticoid used, number of asthma attacks, and asthma control.
RESULTS:
At the start of treatment, there were no significant differences in baseline data, FeNO, and pulmonary function between the two groups (P>0.05). Over the time of treatment, FeNO gradually decreased and pulmonary function parameters were gradually improved in both groups (P<0.001). Compared with the intermittent inhalation group, the daily inhalation group had a better effect in reducing FeNO and increasing the predicted percentage of forced expiratory volume in 1 second (FEV1%pred) (P<0.001). The inhalation method and treatment time had an interaction effect on FeNO and pulmonary function parameters (P<0.001). In the daily inhalation group, FeNO and lung function parameters were improved rapidly and stabilized after 3 months of treatment, while those in the intermittent inhalation group stabilized after 6 months. After 12 months of treatment, there were no significant differences in the increases in body height and body weight and the degree of disease control between the two groups (P>0.05). Compared with the daily inhalation group, the intermittent inhalation group had a significantly lower amount of budesonide inhaled (P<0.05) and a significantly higher number of asthma attacks (P<0.05).
CONCLUSIONS
Intermittent inhalation and daily inhalation of budesonide can achieve the same level of asthma control in children with mild persistent asthma and both have no influence on the increases in body height and body weight. Daily inhalation of budesonide can produce a better efficiency in reduing FeNO and increasing FEV1%pred. Although intermittent inhalation can reduce the amount of glucocorticoid used, it may lead to a higher risk of asthma attacks.
Administration, Inhalation
;
Adolescent
;
Asthma
;
drug therapy
;
Budesonide
;
therapeutic use
;
Child
;
Forced Expiratory Volume
;
Humans
;
Nitric Oxide
3.The effect of budesonide inhalation suspension via transnasal nebulization to the volume of bleeding during endoscopic sinus surgery.
Jinyan XING ; Xinguo LIU ; Yongyuan TIAN
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2014;28(14):1077-1078
Administration, Inhalation
;
Adolescent
;
Adult
;
Aged
;
Blood Loss, Surgical
;
Budesonide
;
administration & dosage
;
Child
;
Endoscopy
;
Humans
;
Middle Aged
;
Nose
;
surgery
;
Young Adult
7.A clinical analysis of nebulized Pulmicort respimat around FESS period.
Yiming JIANG ; Chun ZHANG ; Jiaqing ZHOU ; Zheng ZHOU ; Yanan XU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2007;21(20):939-941
OBJECTIVE:
To evaluate the recent clinical efficiency of nebulized Pulmicort respimat after FESS.
METHOD:
Forty-four patients with chronic sinusitis who received FESS, 21 cases were treated with aerosol therapy: Pulmicort respimat , the other 23 cases were treated with Budesonide aqueous nasal spray. All the patients were asked for return at the day 14. Efficacy was evaluated by measurement of nasal symptom scores and sign scores at day 2 and day 14, the biopsy of the membrane on the gap of sinus maxillary were taken to count the eosinophil cell and neutrophil cell in per hundred inflammation cells under microscope and analyze the statistic of the symptom scores, sign scores, efficiency, percentage of the eosinophil cell and the neutrophil cell between two groups at day 14.
RESULT:
There was no significant differences on the total score between two groups at the day 2, while the therapy group was remarkably lower than that in the control group at the day 14 (P < 0.01). The therapy group had a higher efficacity than the control group but no significance (P > 0.05). The percentage of the eosinophil was no significant differences between two groups (P > 0.05), while the percentage of the neutrophil was lower in the therapy group (P < 0.01).
CONCLUSION
Pulmicort respimat and Budesonide are the same type hormones, butPulmicort respimat is a fine granule mixed liquid, with PARI SINUS nasal spray, it can arrive at the whole cavity of the sinus maxillary and be absorbed faster and in a larger space. We consider that nebulized Pulmicort respimat after FESS can relieve the acute inflammation and oedema, it can also reduce the complication of the surgery. The recent clinical efficiency of the Pulmicort respimat is much better than other aqueous nasal spray.
Administration, Inhalation
;
Administration, Intranasal
;
Adolescent
;
Adult
;
Aged
;
Budesonide
;
administration & dosage
;
Chronic Disease
;
Endoscopy
;
methods
;
Female
;
Humans
;
Intraoperative Period
;
Male
;
Middle Aged
;
Nasal Sprays
;
Sinusitis
;
surgery
;
Young Adult
8.Clinical study of the oxygen drive aerosol inhalation with budesonide and ambroxol in the prevention of adult post-thoracotomy pneumonia.
Gang LI ; Jian Sheng WANG ; Si Da QIN ; Jia ZHANG ; Ning DU ; Jing ZHANG ; Xin SUN ; Hong REN
Journal of Peking University(Health Sciences) 2018;50(5):840-844
OBJECTIVE:
To study the clinical effect of the oxygen drive aerosol in halation with budesonide and ambroxol in the prevention of adult post-thoracotomy pneumonia.
METHODS:
This was a randomized, open and parallel controlled trial. We chose 80 cases of patients in the department of thoracic surgery in the First Affiliated Hospital of Xi'an Jiaotong University which fitted our criteria as the research object. The selected patients were randomly divided into the active group and the control group, and the active group underwent oxygen drive aerosol inhalation (2 mg budesonide combined 60 mg ambroxol) for 3 days before operation, and the control group without preoperative aerosol inhalation, and their postoperative therapy was the same.
RESULTS:
The baseline data showed that the differences in sex, age, disease and smoking were not statistically significant between the two groups, P>0.05. The results of blood gas analysis before 12 hours of operation suggested that, the PaO₂and PaCO₂values of the active group were (88.40±9.40) mmHg and (38.30±6.10) mmHg; The PaO₂and PaCO₂ values of the control group were (85.09±7.18) mmHg and (41.21±3.15) mmHg. And the two groups' P values were 0.029 and 0.011, with statistical differences. There were 3 patients who developed postoperative pneumonia out of 40 patients in the active group, the incidence was 7.50%, but the incidence of control group was 25.00%. The P value was 0.034, with statistical differences. We also analyzed the influence of different diseases and surgical methods on postoperative pneumonia, and the results showed that in the active group and the control group, the incidence of postoperative pneumonia in the patients with esophageal cancer was lower than that in lung cancer patients, and there was a statistically significant difference (P<0.05). In the active group, the numbers of pulmonary deed resection, lobectomy and pulmonary sleeve resection were 2, 21 and 1 cases respectively, and the corresponding numbers in the control group were 2, 21 and 2. Among the two groups, the incidence of postoperative pneumonia in the patients with different surgical methods of lung cancer was statistically significant (P<0.05).
CONCLUSION
If we implement respiratory preparation with budesonide plus ambroxol inhalation for 3 days before operation, we can greatly reduce the incidence of postoperative pneumonia?
Adult
;
Aerosols
;
Ambroxol/administration & dosage*
;
Bronchodilator Agents/administration & dosage*
;
Budesonide/administration & dosage*
;
Drug Therapy, Combination
;
Humans
;
Oxygen
;
Pneumonia/prevention & control*
;
Thoracotomy/adverse effects*
9.Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content.
Zheng-lin LIANG ; Xiu-hua WANG ; Rui NI ; Lan ZHANG ; Uwe MUENSTER ; Shi-rui MAO
Acta Pharmaceutica Sinica 2015;50(9):1180-1185
Using high pressure homogenization method combined with spray-drying, budesonide-loaded chitosan microparticles were prepared and the in vitro release profile was investigated. The microparticles were then blended with lactose using a vortex mixer, influence of mixing speed, mixing time on drug recovery rate and content homogeneity were investigated. Meanwhile, influence of lactose content on drug recovery rate, content homogeneity, powder flowability and in vitro deposition were studied. It turned out that budesonide was released from the microparicles in a sustained manner, with fine particle fraction as high as 46.0%, but the powder flowability was poor. After blending with 10 times of lactose, the drug recovery rate was 96.5%, with relative standard deviation of drug content 2.5%, and fine particle fraction of the formulation increased to 59.6% with good flowability. It's demonstrated that using a vortex mixer, budesonide sustained-release dry powder for inhalation with good recovery and content homogeneity could be prepared, the formulation had good flowability and was suitable for pulmonary inhaling.
Administration, Inhalation
;
Budesonide
;
chemistry
;
Chemistry, Pharmaceutical
;
Chitosan
;
Delayed-Action Preparations
;
chemistry
;
Drug Carriers
;
Lactose
;
chemistry
;
Particle Size
;
Powders